Scleroderma - Reset My Life

09/08/2026

01/08/2026

Can the progression of Scleroderma be predicted?

Yes—but only to a limited extent. No doctor can predict exactly how scleroderma will progress in an individual person. However, several factors can help estimate whether the disease is more likely to remain stable or become more aggressive.

Factors that help predict progression

🕒 1. Disease subtype

Diffuse cutaneous systemic sclerosis (dcSSc): Higher risk of rapid progression, especially during the first 3–5 years.

Limited cutaneous systemic sclerosis (lcSSc): Usually progresses more slowly, although complications such as pulmonary hypertension can develop later.

🫁 2. Lung involvement

A declining lung function (FVC or DLCO) or worsening lung fibrosis on HRCT suggests a higher risk of progression.

❤️ 3. Heart and kidney involvement

New heart rhythm problems, reduced heart function, or signs of kidney involvement require close monitoring because they can indicate more severe disease.

🩸 4. Autoantibodies Certain antibodies are associated with different disease patterns:

Anti-Scl-70 (Topoisomerase I): Higher risk of interstitial lung disease.

Anticentromere antibody (ACA): More often linked with limited disease and a lower risk of severe lung fibrosis.

Anti-RNA polymerase III: Increased risk of rapidly progressive skin disease and scleroderma renal crisis.

✋ 5. Skin thickening Doctors often use the Modified Rodnan Skin Score (mRSS). Rapidly increasing skin thickness early in the disease is associated with a greater risk of internal organ involvement.

🩺 6. Early response to treatment People whose skin, lung function, and symptoms stabilize after treatment generally have a better long-term outlook than those whose disease continues to worsen despite therapy.

The good news:-
Not everyone with scleroderma experiences relentless progression.

Many people reach a stable phase after the first few years.

Early diagnosis, regular monitoring, and appropriate treatment can significantly reduce the risk of serious complications.

Healthy lifestyle measures—avoiding smoking, staying physically active, protecting against Raynaud's attacks, and managing reflux—also support better long-term outcomes.

Recommended monitoring :-
Regular follow-up helps detect progression before symptoms become obvious:

Pulmonary function tests (FVC, DLCO): Every 6–12 months (more often if disease is active)

HRCT of the lungs: When clinically indicated

Echocardiogram: Yearly to screen for pulmonary hypertension and heart involvement

Blood pressure and kidney function: Especially during the first 5 years

Skin assessment (mRSS): At clinic visits

Scleroderma progression cannot be predicted with certainty, but doctors can estimate risk by combining the disease subtype, autoantibodies, skin score, lung function, organ involvement, and how the disease responds to treatment. The earlier changes are recognized, the greater the opportunity to slow progression and preserve quality of life.

Source

1. European Alliance of Associations for Rheumatology (EULAR).
2023 EULAR recommendations for the t

2. European League Against Rheumatism (EULAR)

3. Khanna D, et al.
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Respiratory Research. 2022;23:6.

4. Goh NS, et al.
Interstitial lung disease in systemic sclerosis: A simple staging system.
American Journal of Respiratory and Critical Care Medicine. 2008;177:1248–1254.

5. Solomon JJ, et al.
Systemic sclerosis-associated interstitial lung disease.
European Respiratory Review. 2013;22:6–19

6. Clements PJ, et al.
Skin thickness score in systemic sclerosis: an assessment of interobserver variability.
Journal of Rheumatology. 1995;22:1281–1285.

7. Amjadi S, et al.
Performance of the Modified Rodnan Skin Score in systemic sclerosis.
Journal of Scleroderma and Related Disorders. 2021.

8. Ho KT, Reveille JD.
The clinical relevance of autoantibodies in scleroderma.
Arthritis Research & Therapy. 2003;5:80–93.

9. Nihtyanova SI, Denton CP.
Autoantibodies as predictive tools in systemic sclerosis.
Nature Reviews Rheumatology. 2010;6:112–116

10. Denton CP, Khanna D.
Systemic sclerosis.
The Lancet. 2017;390:1685–1699.

11. Varga J, Trojanowska M, Kuwana M.
Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities.
Journal of Scleroderma and Related Disorders. 2023.

01/08/2026

30/07/2026

It’s more than paying for medications.

First, the costs often begin long before a diagnosis. Many people spend months—or even years—paying for consultations, blood tests, scans, and referrals while searching for answers.

Then, after a diagnosis, the expenses continue. Regular checkups, specialist visits, imaging, and laboratory tests become part of life.

In addition, many people need lifelong medications. These treatments can be costly, but they are essential for managing the disease and slowing its progression.

Unfortunately, not everyone has health insurance. Even those who do may find that important medications, treatments, or specialist visits are only partially covered—or not covered at all.

Moreover, access to healthcare is not equal around the world. Many patients live in countries where specialists are limited and life-saving treatments remain out of reach.

As a result, many families travel long distances to receive proper care, adding transportation, accommodation, and other expenses to an already overwhelming financial burden.

Despite these challenges, people living with scleroderma continue to fight every day. They do everything they can to access the care they need and protect their health.

That is why greater awareness matters. Earlier diagnosis, better access to treatment, stronger support, and continued research can help ease the financial burden for people living with scleroderma.